

UNITED STATES PATENT AND TRADEMARK OFFICE

Application. No. : 10/714,506
First Named Inventor : Sanjay (NMI) Awasthi
Filing Date : November 13, 2003
Title : ANTIBODIES FOR CANCER PROTECTION
Group Art Unit : 1642
Examiner : Brandon J. Fetterolf
Confirmation No. : 1056




DECLARATION UNDER 37 § CFR 1.131

We, Sanjay Awasthi, and Sharad S. Singhal, declare that:

1. We are the named inventors in the above-identified U.S. Application No. 10/714,506, filed November 13, 2003, and having a priority filing date of November 13, 2002.

2. We conceived and reduced to practice in the United States of America the invention disclosed and claimed in the above-identified application prior to March 2002, the date of publication of Awasthi et al. (Proc. Am. Assoc. Cancer. Res. March 2002;43 Abstract #4717).


3. All statements made herein of our own knowledge are true and all statements made on information and belief are believed to be true. These statements are made with the knowledge that willful false statements so made are punishable by fine or imprisonment or both under section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.


Sanjay Awasthi

1/6/2005
Date

Sharad S. Singhal

Date



Arlington, TX

Dr. Larry Matherly
Associate Professor
Karmanos Cancer Institute
110 E. Warren Ave.
Detroit MI 48201

Dear Dr. Matherly

I am sending copies of 14 figures along with figure legends for the abstract "Anti-RLIP76 Antibodies Induce Apoptosis and Enhance Doxorubicin Cytotoxicity in Lung Cancer Cells". These figures have been prepared for the poster and will be communicated as part of a complete manuscript within the next 2 weeks to J. Clin. Invest. A preliminary version of the abstract is also enclosed. I hope you will find these results interesting and worthy of oral presentation.

Sincerely,

Sanjay Awasthi, M.D.
Professor, Biochemistry